This article summarized the latest R&D progress of Tigecycline, the Mechanism of Action for Tigecycline, and the drug target R&D trends for Tigecycline.

Myostatin, a member of the transforming growth factor beta (TGF‐β) superfamily that is highly expressed in skeletalmuscle, was first described in 1997.

This article summarized the latest R&D progress of Trilostane, the Mechanism of Action for Trilostane, and the drug target R&D trends for Trilostane.

ImmunoGenesis announced the first patient treatment in their Phase 1a/1b trial using IMGS-001 at The University of Texas MD Anderson Cancer Center.

This article summarized the latest R&D progress of Plinabulin, the Mechanism of Action for Plinabulin, and the drug target R&D trends for Plinabulin.

Chk1, also known as checkpoint kinase 1, is a crucial protein kinase involved in the regulation of cell cycle progression and DNA damage response in the human body.

This article summarized the latest R&D progress of Pindolol, the Mechanism of Action for Pindolol, and the drug target R&D trends for Pindolol.

Merck has declared that a fresh BLA for sotatercept has been approved for accelerated assessment by the U.S. FDA.

This article summarized the latest R&D progress of Pertuzumab, the Mechanism of Action for Pertuzumab, and the drug target R&D trends for Pertuzumab.

This article will review currently applied listed GPCR-targeting drugs, and the associated popular GPCR class targets and drug development opportunities worth paying attention to.

This article summarized the latest R&D progress of Panitumumab, the Mechanism of Action for Panitumumab, and the drug target R&D trends for Panitumumab.

STK-012 is designed specifically to activate antigen-triggered T cells, crucial for powerful anti-cancer effects, while avoiding broader activation of other lymphocytes, such as NK cells related to IL-2 toxicity.